This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Spero Therapeutics, LLC
Drug Names(s): S. aureus Polysaccharide Conjugate Vaccine
Description: StaphVAX is Nabi’s recombinant conjugate vaccine against the bacterium Staphylococcus aureus. StaphVAX is designed to stimulate a patient's immune system to produce antibodies to S. aureus that provide active, long-term protection from the bacteria. StaphVAX targets S. aureus types 5 and 8, which are responsible for approximately 85 percent of S. aureus infections.
Biota and Nabi
In September 2007, Nabi Biopharmaceuticals announced that it had entered into a definitive agreement with Biotest AG to sell the Nabi Biologics strategic business unit (SBU) to Biotest Pharmaceuticals Corporation for $185 million. The acquisition of Biologics SBU's products includes Nabi-HB, Civacir, and Altastaph. Nabi will retain its Pharmaceuticals strategic business unit assets, including NicVAX and its investigational StaphVAX programs.
As part of the Purchase Agreement, Nabi will grant Biotest Pharmaceuticals a right of first negotiation and a right of first refusal to obtain rights to utilize StaphVAX and to license the StaphVAX intellectual property that are necessary to enable Biotest Pharmaceuticals to use StaphVAX solely for purposes relating to Altastaph.
In December 2007, Biotest completed its acquisition of Nabi's Biologics strategic business unit.
In April 2012, Nabi Biopharmaceuticals announced plans to merge with Biota Holdings. The...See full deal structure in Biomedtracker
Pink Sheet Nabi revises StaphVax study
Pink Sheet Nabi’s StaphVAX Development Back On Track
Additional information available to subscribers only: